

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Please amend the claims as follows

1. (Original) Sachet for a pharmaceutical composition, comprising the layers:
 - i) paper;
 - ii) bonding layer;
 - iii) barrier layer; and
 - iv) sealing layer.
2. (Original) Sachet according to claim 1, wherein said barrier layer is an aluminum foil, said bonding layer is preferably of polyethylene, and said sealing layer is preferably a low density polyethylene.
3. (Currently Amended) Sachet according to claim 1 or 2, wherein said paper i) has a weight per unit area of 10-100 g/m².
4. (Original) Sachet according to claim 3, wherein said paper i) has a weight per unit area of 30-70 g/m².
5. (Original) Sachet according to claim 4, wherein said paper i) has a weight per unit area of 40-60 g/m².
6. (Currently Amended) Sachet according to claim 1 any of the preceding claims, wherein said bonding layer ii) has a weight per unit area of 6-20 g/m².
7. (Original) Sachet according to claim 6, wherein said bonding layer ii) has a weight per unit area of 9-18 g/m².

8. (original) Sachet according to claim 7, wherein said bonding layer ii) has a weight per unit area of 12-15 g/m².

9. (Currently Amended) Sachet according to claim 1 ~~any of the preceding claims~~, wherein said sealing layer iv) has a thickness of 15-50 μ m.

10. (Currently Amended) Sachet according to claim 1 ~~any of the preceding claims~~, wherein said sealing layer iv) has a weight per unit area of 10-100 g/m², more preferred 15-75 g/m², preferably 20-50 g/m², more preferably 30-40 g/m², most preferred 35 g/m².

11. (Currently Amended) Sachet according to claim 1 ~~any of the preceding claims~~, wherein said barrier layer iii) has a thickness of 6-30 μ m, more preferred 7-25 μ m, preferably 9-25 μ m, more preferred 8-20 μ m, preferably 9-15 μ m, more preferred 12 μ m.

12. (Currently Amended) Sachet according to claim 1 ~~any of the preceding claims~~, containing a pharmaceutical formulation.

13. (Original) Sachet according to claim 12, wherein said pharmaceutical formulation comprises mesalazine or a pharmaceutically acceptable salt thereof.

14. (Currently Amended) Sachet according to claim 12 ~~or 13~~, said sachet containing an oral pharmaceutical formulation in the form of a granulate comprising more than 55% by weight of mesalazine or a pharmaceutically acceptable salt thereof.

15. (Currently Amended) Use of sachet according to claim
~~1 any of the preceding claims~~ for a pharmaceutical
composition.

16. (Currently Amended) Use of a sachet according to
claim 1 any of the claims 1 - 14 for medical purposes.